(Q79831019)
Statements
A multicentre phase I and pharmacokinetic study of BN80915 (diflomotecan) administered daily as a 20-min intravenous infusion for 5 days every 3 weeks to patients with advanced solid tumours (English)
L Scott
O Soepenberg
J Verweij
M J A de Jonge
A S Th Planting
D McGovern
P Principe